IL286703A - Ghrh or its analogues for use in the treatment of liver disease - Google Patents
Ghrh or its analogues for use in the treatment of liver diseaseInfo
- Publication number
- IL286703A IL286703A IL286703A IL28670321A IL286703A IL 286703 A IL286703 A IL 286703A IL 286703 A IL286703 A IL 286703A IL 28670321 A IL28670321 A IL 28670321A IL 286703 A IL286703 A IL 286703A
- Authority
- IL
- Israel
- Prior art keywords
- ghrh
- analogues
- treatment
- hepatic disease
- hepatic
- Prior art date
Links
- 101150102363 Ghrh gene Proteins 0.000 title 1
- 208000019423 liver disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962826284P | 2019-03-29 | 2019-03-29 | |
| US201962861187P | 2019-06-13 | 2019-06-13 | |
| PCT/US2020/025180 WO2020205498A1 (en) | 2019-03-29 | 2020-03-27 | Ghrh or analogues thereof for use in treatment of hepatic disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL286703A true IL286703A (en) | 2021-10-31 |
Family
ID=72607731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL286703A IL286703A (en) | 2019-03-29 | 2021-09-26 | Ghrh or its analogues for use in the treatment of liver disease |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10799562B1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3947426A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2022527190A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20210145226A (cg-RX-API-DMAC10.html) |
| CN (1) | CN113646327A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2020253828A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3133319A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL286703A (cg-RX-API-DMAC10.html) |
| SG (1) | SG11202110469PA (cg-RX-API-DMAC10.html) |
| WO (1) | WO2020205498A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020205498A1 (en) * | 2019-03-29 | 2020-10-08 | The General Hospital Corporation | Ghrh or analogues thereof for use in treatment of hepatic disease |
| CA3183299A1 (en) * | 2020-07-05 | 2022-01-13 | Christian Marsolais | Low-dose pharmaceutical compositions of ghrh analogs and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009010675A (es) * | 2007-04-04 | 2009-10-23 | Theratechnologies Inc | Formulaciones farmaceuticas de moleculas de la hormona liberadora de la hormona delcrecimiento humana. |
| US9163091B2 (en) * | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
| US20150174207A1 (en) * | 2013-12-24 | 2015-06-25 | University Of Miami | Methods for treating cancer with ghrh agonists |
| EP3362053A4 (en) * | 2015-10-16 | 2019-04-17 | Hadasit Medical Research Services and Development Ltd. | TREATMENT OF NON-ALCOHOLIC FATTYLENE OR NON-ALCOHOLIC STEATOHEPATITIS WITH 6-MERCAPTOPURIN WITH DELAYED RELEASE |
| MX2018012716A (es) * | 2016-04-19 | 2019-02-11 | Griffon Pharmaceuticals Inc | Peptidos bioactivos pegilados y usos de los mismos. |
| EP4467158A3 (en) * | 2018-02-14 | 2025-02-19 | Lumos Pharma, Inc. | Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis |
| WO2020205498A1 (en) * | 2019-03-29 | 2020-10-08 | The General Hospital Corporation | Ghrh or analogues thereof for use in treatment of hepatic disease |
| JP2023548156A (ja) * | 2020-10-30 | 2023-11-15 | ザ ジェネラル ホスピタル コーポレイション | 肝疾患の評価のためのキット、試薬、及び方法 |
| WO2022104289A1 (en) * | 2020-11-16 | 2022-05-19 | The Regents Of The University Of California | Use of pharmaceutical doses of niacin, or an analog thereof, for the regression or reversal of fibrosis and/or liver cirrhosis |
-
2020
- 2020-03-27 WO PCT/US2020/025180 patent/WO2020205498A1/en not_active Ceased
- 2020-03-27 AU AU2020253828A patent/AU2020253828A1/en not_active Abandoned
- 2020-03-27 US US16/832,128 patent/US10799562B1/en active Active
- 2020-03-27 EP EP20784029.9A patent/EP3947426A4/en not_active Withdrawn
- 2020-03-27 KR KR1020217034940A patent/KR20210145226A/ko not_active Ceased
- 2020-03-27 CN CN202080025127.2A patent/CN113646327A/zh active Pending
- 2020-03-27 SG SG11202110469PA patent/SG11202110469PA/en unknown
- 2020-03-27 JP JP2021557925A patent/JP2022527190A/ja active Pending
- 2020-03-27 CA CA3133319A patent/CA3133319A1/en active Pending
- 2020-09-11 US US17/018,878 patent/US10946073B2/en active Active
-
2021
- 2021-02-08 US US17/170,579 patent/US11738066B2/en active Active
- 2021-09-26 IL IL286703A patent/IL286703A/en unknown
-
2023
- 2023-07-12 US US18/351,169 patent/US12233107B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10946073B2 (en) | 2021-03-16 |
| EP3947426A4 (en) | 2023-01-04 |
| US10799562B1 (en) | 2020-10-13 |
| WO2020205498A1 (en) | 2020-10-08 |
| KR20210145226A (ko) | 2021-12-01 |
| SG11202110469PA (en) | 2021-10-28 |
| CN113646327A (zh) | 2021-11-12 |
| US20200405816A1 (en) | 2020-12-31 |
| US20210177943A1 (en) | 2021-06-17 |
| US12233107B2 (en) | 2025-02-25 |
| CA3133319A1 (en) | 2020-10-08 |
| JP2022527190A (ja) | 2022-05-31 |
| US20240091316A1 (en) | 2024-03-21 |
| US20200306345A1 (en) | 2020-10-01 |
| US11738066B2 (en) | 2023-08-29 |
| EP3947426A1 (en) | 2022-02-09 |
| AU2020253828A1 (en) | 2021-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3577135T3 (pl) | Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5 | |
| IL274578A (en) | Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases | |
| SMT202100468T1 (it) | 24-idrossisteroli sostituiti in posizione 11 per l'uso nel trattamento delle condizioni correlate all'nmda | |
| PL3829628T3 (pl) | Kompozycja farmaceutyczna do zastosowania w leczeniu lub zapobieganiu chorobie związanej z C5 | |
| IL254142B (en) | Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent | |
| SI3806898T1 (sl) | Antagonist Gremlin-1 za uporabo pri zdravljenju raka | |
| ZA201704957B (en) | Composition for the treatment of hepatic veno-occlusive disease | |
| GB2561945B (en) | Tissue stain and use thereof | |
| EP3261446A4 (en) | Methods and compositions for the treatment or prevention of parkinson's disease | |
| EP3592377A4 (en) | DOSAGE FORMS OF TISSUE KALLIKREIN 1 | |
| IL272495A (en) | Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases | |
| LT3124048T (lt) | Kompozicija skirta vartoti per burną gastroezofaginio refliukso ligos ar skausmo gydymui | |
| PL3285755T3 (pl) | Chlorowodorek kreatyny do leczenia choroby Huntingtona | |
| PL3137097T3 (pl) | Leczenie i profilaktyka choroby Alzheimera (AD) | |
| GB2574954B (en) | Tissue scaffold and scaffold composition | |
| IL254252A0 (en) | History of Tetrahydrofuran-Oahe Aminohydrothiazine Usefulness in the Treatment of Alzheimer's Disease | |
| PL3352742T3 (pl) | Kompozycje zawierające triterpenoidy do leczenia choroby alzheimera i choroby parkinsona | |
| ES2660372T8 (es) | Sustancias y procedimientos para la utilización en la prevención y/o el tratamiento en la enfermedad de Huntington | |
| PT3137094T (pt) | Tratamento e prevenção da doença de alzheimer (da) | |
| HK40071625A (en) | Ghrh or analogues thereof for use in treatment of hepatic disease | |
| ITUA20163037A1 (it) | Formulazioni per uso nel trattamento o prevenzione di disturbi urologici | |
| PL3352777T3 (pl) | Engrailed do stosowania w leczeniu uszkodzenia dna u pacjentów cierpiących na chorobę parkinsona | |
| PT3137093T (pt) | Tratamento e prevenção da doença de alzheimer (da) | |
| ZA201801945B (en) | Compositions and methods for the treatment of parkinson's disease | |
| GB201521442D0 (en) | Polytpeptides and analogues thereof for use in the treatment of diabetes and bone disorders |